Position in EXEL
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$2,855,872
-$1,769,857 QoQ
Shares Held
52,488
-51.3% QoQ
Ownership
0.021%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#225
of 739 holders
Holding Since
Sep 2024
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Entropy Technologies, LP holds $54,448,699 across 47 Biotechnology names. EXEL ranks #6 (5.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
41,204 | $12,403,640 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,606 | $5,989,725 | |
| 3 | INSM |
INSMED Inc
|
45,469 | $4,847,904 | |
| 4 | RPRX |
Royalty Pharma plc
|
58,767 | $3,295,065 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
36,815 | $2,919,061 | |
| 6 | EXEL |
Exelixis, Inc.
This page
|
52,488 | $2,855,872 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
27,148 | $2,021,983 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
24,583 | $1,547,254 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,855,872 | 52,488 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $4,625,729 | 107,851 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,067,917 | 24,365 | Shares | Sole | 2026-02-13 | |
| 2024-12-31 | $723,642 | 21,731 | Shares | Sole | 2025-01-28 | |
| 2024-09-30 | $474,885 | 18,300 | Shares | Sole | 2024-11-04 | |
| No filing history on record for this holder in this stock. | ||||||